FAQ on Beam Therapeutics' Presentation of New Sickle Cell Data from BEACON Trial at EHA2025

What is BEAM-101 and what does it target?

BEAM-101 is an investigational, one-time ex vivo cell therapy developed by Beam Therapeutics targeting severe vaso-occlusive crises in sickle cell disease (SCD), aiming to address the root cause of SCD.

Where and when will the new data from the BEACON trial be presented?

The new data will be presented at the European Hematology Association 2025 Congress, June 12-15 in Milan, with specific highlights during poster sessions on June 13.

How many patients’ data will be covered in the presentation?

The presentation will cover safety and efficacy outcomes in 17 patients participating in the BEACON Phase 1/2 trial.

What additional topics will the presentations explore?

Additional presentations will explore biomarkers, manufacturing advances, and red blood cell health post-treatment with BEAM-101.

Will there be a webcast to review the EHA highlights?

Yes, Beam Therapeutics will host a webcast on June 13 at 4:00 p.m. ET to review highlights from the EHA2025 Congress.

What is Beam Therapeutics’ focus as a biotechnology company?

Beam Therapeutics is committed to establishing a leading, fully integrated platform for precision genetic medicines, utilizing base editing technology to enable precise, predictable, and efficient single base changes without making double-stranded breaks in the DNA.

Where can I find more information about Beam Therapeutics?

For more information, visit Beam Therapeutics’ website at: https://beamtx.com/.

Where can I view the full press release about this announcement?

The full press release can be viewed at: https://ibn.fm/kBIIB.